Exhibit 16.1


July 26, 2021


Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549-7561


Ladies and Gentlemen:


We have read Titan Pharmaceuticals, Inc.’s statements included under Item 4.01 of its Form 8-K dated July 26, 2021, and are in agreement with the statements contained therein concerning our firm in response to Item 304(a) of Regulation S-K.


Very truly yours,


/s/ OUM & Co. LLP